Albireo Pharma, Inc.

Albireo Pharma is a biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome. Albireo also expects to complete IND-enabling studies for a new preclinical candidate this year. Albireo was spun out from AstraZeneca in 2008, with sites in Boston, Massachusetts and Gothenburg, Sweden.

!LIVE IM STREAM!

Aktuelle Diagnostik und Therapie familiärer Cholestase Syndrome
Prof. Ulrich Baumann and Dr. Eva-Doreen Pfister (Medizinische Hochschule Hannover)

Donnerstag 12.11.2020 12:30 – 13:30 Uhr

Lunchsymposium der Albireo Pharma, Inc.

Produkte / Medizinische Studien

PFIC Voices Snapshot: Family Montage

YouTube

Mit dem Laden des Videos akzeptieren Sie die Datenschutzerklärung von YouTube.
Mehr erfahren

Video laden

Our Focus

Albireo is focused on bringing a treatment to patients suffering from cholestatic liver diseases, such as PFIC, Alagille syndrome, and biliary atresia. The PEDFIC 1 study is the largest prospective clinical trial ever conducted in PFIC. It is a rich source of data that should fundamentally change the way that PFIC is managed and provide interesting information on odevixibat. We’re seeing some very interesting trends for the effect of odevixibat within certain patient groups. We’re studying that closely as we speak.

Vimeo

Mit dem Laden des Videos akzeptieren Sie die Datenschutzerklärung von Vimeo.
Mehr erfahren

Video laden

Aus datenschutzrechlichen Gründen benötigt Vimeo Ihre Einwilligung um geladen zu werden. Mehr Informationen finden Sie unter Datenschutz.
Akzeptieren

DISCLAIMER

The following video is intended for medical personnel only!

Vimeo

Mit dem Laden des Videos akzeptieren Sie die Datenschutzerklärung von Vimeo.
Mehr erfahren

Video laden

Aus datenschutzrechlichen Gründen benötigt Vimeo Ihre Einwilligung um geladen zu werden. Mehr Informationen finden Sie unter Datenschutz.
Akzeptieren

About Odevixibat

Odevixibat is an investigational drug that is being developed here at Albireo. It is an ileal bile acid transporter inhibitor or an IBAT inhibitor. It works by being within the intestine and binding reversibly and potently to those IBATs. IBATs are responsible for the reuptake of bile from the intestine into the circulation. By blocking that, odevixibat ultimately lowers the systemic bile acid levels, which may contribute to a decrease in pruritus in these children.